Ann: Imugene Investor Webinar - MAST Study Update, page-73

Also ... they are seeing great signals in the MONO treatments, and at only mid dose. This is very, very positive for several reasons.

Assuming the trial goes on to prove that MONO works as well or maybe better than combo, then it is massive for IMU for a couple of reasons that I can think of. There may be more for sure but

1. MONO means no need to combo with those toxic treatment available out there. Especially given that CF33 has shown to be safe and tolerable so far even at higher doses.

2. MONO means anybody that got hold of CF33 will be king of any targeted solid tumour market such as the bile duct cancer that IMU is hoping to expand on. So which BP is gonna blink first and which will say 'over my dead body'. So when the first BP blink, don't take the first offer because there will be more and better offers

Cheers